Prostaglandin E2 inhibits human lung fibroblast chemotaxis through disparate actions on different E-prostanoid receptors

American Journal of Respiratory Cell and Molecular Biology

Volumn 44, Issue 1, 2010, Pages 99-107

  Li, Ying Ji ^a   Wang, Xing Qi ^b   Sato, Tadashi ^b   Kanaji, Nobuhiro ^b   Nakanishi, Masanori ^b   Kim, Miok ^d   Michalski, Joel ^b   Nelson, Amy J ^b   Sun, Jian Hong ^b   Farid, Maha ^b   Basma, Hesham ^b   Patil, Amol ^b   Toews, Myron L ^c   Liu, Xiangde ^b   Rennard, Stephen I ^b  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d Jeju Environment Research Institute   (South Korea)

Author keywords

Cell migration; EP receptors; Human lung fibroblast

Indexed keywords

6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; E PROSTANOID RECEPTOR; E PROSTANOID RECEPTOR ANTAGONIST; FIBRONECTIN; ONO 8713; ONOAE 1259; ONOAE 1329; ONOAE 248; ONOAE 3208; ONOAE 3240; ONODI 004; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROSTANOID RECEPTOR; PROSTANOID RECEPTOR EP1 AGONIST; PROSTANOID RECEPTOR EP2 AGONIST; PROSTANOID RECEPTOR EP3 AGONIST; PROSTANOID RECEPTOR EP4 AGONIST; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E RECEPTOR 3; PTGER1 PROTEIN, HUMAN; PTGER2 PROTEIN, HUMAN; PTGER3 PROTEIN, HUMAN; PTGER4 PROTEIN, HUMAN;

ARTICLE; CELL ASSAY; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; DRUG INHIBITION; DRUG SELECTIVITY; FETUS LUNG; GENE REPRESSION; HUMAN; HUMAN CELL; LUNG FIBROBLAST; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE REPAIR; WESTERN BLOTTING; WOUND CLOSURE; WOUND HEALING; BRONCHUS; CELL CULTURE; CELL PROLIFERATION; DRUG EFFECT; DRUG POTENTIATION; FIBROBLAST; GENETICS; METABOLISM; RNA INTERFERENCE; TIME;

BLOTTING, WESTERN; BRONCHI; CELL PROLIFERATION; CELLS, CULTURED; CHEMOTAXIS; DINOPROSTONE; FIBROBLASTS; FIBRONECTINS; HUMANS; RECEPTORS, PROSTAGLANDIN E; RECEPTORS, PROSTAGLANDIN E, EP1 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; WOUND HEALING;

EID: 78650640662     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2009-0163OC     Document Type: Article

References (47)

1. Selman M, Pardo A. The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003; 29(Suppl. 3)S93-S97. (Pubitemid 37070317)
2. Pardo A, Selman M. Idiopathic pulmonary fibrosis: new insights in its pathogenesis. Int J Biochem Cell Biol 2002;34:1534-1538.
3. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, Parsons JT, Horwitz AR. Cell migration: integrating signals from front to back. Science 2003;302:1704-1709.
4. Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell 1996;84:359-369.
5. Suganuma H, Sato A, Tamura R, Chida K. Enhanced migration of fibroblasts derived from lungs with fibrotic lesions. Thorax 1995;50: 984-989.
6. White ES, Thannickal VJ, Carskadon SL, Dickie EG, Livant DL, Markwart S, Toews GB, Arenberg DA. Integrin alpha4beta1 regulates migration across basement membranes by lung fibroblasts: a role for phosphatase and tensin homologue deleted on chromosome 10. Am J Respir Crit Care Med 2003;168:436-442.
7. Togo S, Holz O, Liu X, Sugiura H, Kamio K, Wang X, Kawasaki S, Ahn Y, Fredriksson K, Skold CM, et al. Lung fibroblast repair functions in COPD patients are altered by multiple mechanisms. Am J Respir Crit Care Med 2008;178:248-260.
8. Nakamura Y, Romberger DJ, Tate L, Ertl RF, Kawamoto M, Adachi Y, Mio T, Sisson JH, Spurzem JR, Rennard SI. Cigarette smoke inhibits lung fibroblast proliferation and chemotaxis. Am J Respir Crit Care Med 1995;151:1497-1503.
9. Kohyama T, Ertl RF, Valenti V, Spurzem J, Kawamoto M, Nakamura Y, Veys T, Allegra L, Romberger D, Rennard SI. Prostaglandin E2 inhibits fibroblast chemotaxis. Am J Physiol 2001;281:L1257-L1263.
10. White ES, Atrasz RG, Dickie EG, Aronoff DM, Stambolic V, Mak TW, Moore BB, Peters-Golden M. Prostaglandin E2 inhibits fibroblast migration by E-prostanoid 2 receptor-mediated increase in PTEN activity. Am J Respir Cell Mol Biol 2005;32:135-141.
11. Bitterman PB, Wewers MD, Rennard SI, Adelberg S, Crystal RG. Modulation of alveolar macrophage-driven fibroblast proliferation by alternative macrophage mediators. J Clin Invest 1986;77:700-708.
12. Goldring MB. Modulation of recombinant interleukin 1 of synthesis of types I and III collagens and associated procollagen mRNA levels in cultured human cells. J Biol Chem 1987;262:16724-16729.
13. Goldring MB, Suen LF, Yamin R, Lai WF. Regulation of collagen gene expression by prostaglandins and interleukin-1beta in cultured chondrocytes and fibroblasts. Am J Ther 1996;3:9-16.
14. Mio T, Adachi Y, Romberger DJ, Spurzem JR, Ertl RF, Carnevali S, Rennard SI. Human bronchial epithelial cells modulate collagen gel contraction by fibroblasts. Am J Respir Crit Care Med 1995;151:A561.
15. Cruz-Gervis R, Stecenko AA, Dworski R, Lane KB, Loyd JE, Pierson R, King G, Brigham KL. Altered prostanoid production by fibroblasts cultured from the lungs of human subjects with idiopathic pulmonary fibrosis. Respir Res 2002;3:17.
16. Pueringer RJ, Schwartz DA, Dayton CS, Gilbert SR, Hunninghake GW. The relationship between alveolar macrophage TNF, IL-1, and PGE2 release, alveolitis, and disease severity in sarcoidosis. Chest 1993;103: 832-838.
17. Borok Z, Gillissen A, Buhl R, Hoyt RF, Hubbard RC, Ozaki T, Rennard SI, Crystal RG. Augmentation of functional prostaglandin E levels on the respiratory epithelial surface by aerosol administration of prostaglandin E. Am Rev Respir Dis 1991;144:1080-1084.
18. Sturm EM, Schratl P, Schuligoi R, Konya V, Sturm GJ, Lippe IT, PeskarBA, Heinemann A. Prostaglandin E2 inhibits eosinophil trafficking through E-prostanoid 2 receptors. J Immunol 2008;181:7273-7283.
19. Watson E, Sweeney C, Steensma K. Arachidonate metabolites in bronchoalveolar lavage fluid from horses with and without COPD. Equine Vet J 1992;24:379-381.
20. Vancheri C, Mastruzzo C, Sortino MA, Crimi N. The lung as a privileged site for the beneficial actions of PGE2. Trends Immunol 2004;25: 40-46.
21. Konstan M, Walenga R, Hilliard K, Hilliard J. Leukotriene B4 markedly elevated in the in the epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis 1993;148:896-901.
22. Funahashi A, Harland R, LeFever A. Association of increased prostaglandin E2 content in bronchoalveolar lavage fluid and intrathoracic malignancy. Chest 1994;106:166-172.
23. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007; 282:11613-11617.
24. Norel X, de Montpreville V, Brink C. Vasoconstriction induced by activation of EP1 and EP3 receptors in human lung: effects of ONOAE-248, ONO-DI-004, ONO-8711 or ONO-8713. Prostaglandins Other Lipid Mediat 2004;74:101-112.
25. Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubi F, Ichikawa A, Narumiya S, Suda T. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 2000;141:1554-1559.
26. Bradbury D, Clarke D, Seedhouse C, Corbett L, Stocks J, Knox A. Vascular endothelial growth factor induction by prostaglandin E2 in human airway smooth muscle cells is mediated by e prostanoid EP2/EP4 receptors and SP-1 transcription factor binding sites. J Biol Chem 2005;280:29993-30000.
27. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 1997;122:217-224.
28. Amano H, Hayashi I, Endo H, Kitasato H, Yamashina S, Maruyama T, Kobayashi M, Satoh K, Narita M, Sugimoto Y, et al. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 2003;197:221-232.
29. Yang L, Huang Y, Porta R, Yanagisawa K, Gonzalez A, Segi E, Johnson DH, Narumiya S, Carbone DP. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res 2006;66:9665-9672.
30. Kabashima K, Saji T, Murata T, Nagamachi M, Matsuoka T, Segi E, Tsuboi K, Sugimoto Y, Kobayashi T, Miyachi Y, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 2002;109:883-893.
31. Kamio K, Sato T, Liu X, Sugiura H, Togo S, Kobayashi T, Kawasaki S, Wang X, Mao L, Ahn Y, et al. Prostacyclin analogs stimulate VEGF production from human lung fibroblasts in culture. Am J Physiol Lung Cell Mol Physiol 2008;294:L1226-L1232.
32. HashimotoM,Wang X,Mao L, Kobayashi T, Kawasaki S,Mori N, Toews ML, Kim HJ, Cerutis DR, Liu X, et al. Sphingosine 1-phosphate potentiates human lung fibroblast chemotaxis through the S1P2 receptor. Am J Respir Cell Mol Biol 2008;39:356-363.
33. Powis G, Bonjouklian R, Berggren MM, Gallegos A, Abraham R, Ashendel C, Zalkow L, Matter WF, Dodge J, Grindey G, et al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res 1994;54:2419-2423.
34. Aktories K. Bacterial toxins that target Rho proteins. J Clin Invest 1997; 99:827-829. (Pubitemid 27123617)
35. Liu X, Kohyama T, Wang H, Zhu YK, Wen FQ, Kim HJ, Romberger DJ, Rennard SI. Th2 cytokine regulation of Type I collagen gel contraction mediated by human lung mesenchymal cells. Am J Physiol 2002;282:L1049-L1056.
36. Armstrong RA. Investigation of the inhibitory effects of PGE2 and selective EP agonists on chemotaxis of human neutrophils. Br J Pharmacol 1995;116:2903-2908.
37. Hill HR, Estensen RD, Quie PG, Hogan NA, Goldberg ND. Modulation of human neutrophil chemotactic responses by cyclic 3′,5′-guanosine monophosphate and cyclic 3′,5′-adenosine monophosphate. Metabolism 1975;24:447-456.
38. Oppenheimer-Marks N, Kavanaugh AF, Lipsky PE. Inhibition of the transendothelial migration of human t lymphocytes by prostaglandin E2. J Immunol 1994;152:5703-5713.
39. Freitas AA, Bognacki J. The role of locomotion in lymphocyte migration. Immunology 1979;36:247-255.
40. Kaneko T, Alvarez R, Ueki IF, Nadel JA. Elevated intracellular cyclic amp inhibits chemotaxis in human eosinophils. Cell Signal 1995;7:527-534.
41. Savla U, Appel HJ, Sporn PH, Waters CM. Prostaglandin E(2) regulates wound closure in airway epithelium. Am J Physiol Lung Cell Mol Physiol 2001;280:L421-L431.
42. Stork PJ, Schmitt JM. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 2002;12:258-266.
43. Kawasaki H, Springett GM, Mochizuki N, Toki S, Nakaya M, Matsuda M, Housman DE, Graybiel AM. A family of cAMP-binding proteins that directly activate RAP1. Science 1998;282:2275-2279.
44. Offermanns S, Mancino V, Revel JP, Simon MI. Vascular system defects and impaired cell chemokinesis as a result of galpha13 deficiency. Science 1997;275:533-536.
45. Montuschi P. Exhaled breath condensate analysis in patients with COPD. Clin Chim Acta 2005;356:22-34.
46. Verhoeven GT, Garrelds IM, Hoogsteden HC, Zijlstra FJ. Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease. Mediators Inflamm 2001;10:21-26.
47. Janssen LJ. Isoprostanes: an overview and putative roles in pulmonary pathophysiology. Am J Physiol Lung Cell Mol Physiol 2001;280: L1067-L1082.